Table 6.
Phase I studies of alternative regimens for late relapses in MM.
| Treatment | No. of Patients | Overall Response % | PFS—Months | OS—Months | Grade ≥ 3 AE | Median (Range) of Prior Lines of Therapy |
|---|---|---|---|---|---|---|
| KPd [76] | 32 | 50 | 7.2 | 20.6 | 63% | 6 (2−12) |
| IxaPd [77] | 31 | 48 | 8.6 | NR | 74% | 2 (1−5) |
| PanKd [78] | 30 | 57 | 8 | 23 | 63% | 4 (1−8) |
Abbreviations: PFS: Progression free survival; OS: Overall survival, AE: Adverse events; NR: Not reached; KPd: Carfilzomib, pomalidomide, dexamethasone; IxaPd: Ixazomib, pomalidomide, dexamethasone; PanKd: Panobinostat, carfilzomib, dexamethasone.